Pancreatic Cancer - Articles and news items

NICE does not recommend Shire’s pancreatic cancer drug

Industry news / 3 April 2017 / Niamh Marriott, Junior Editor

The National Institute or Health and Care Excellence (NICE) has published final guidance that does not recommend pegylated liposomal irinotecan (Onivyde, Shire).

EryTech completes patient enrolment in Phase 2 pancreatic cancer trial

Industry news / 28 September 2016 / Niamh Louise Marriott, Digital Content Producer

For the treatment of pancreatic cancer, EryTech are now looking to develop ‘tumour starvation’ treatments for acute leukaemia and have enrolled their…

Onivyde receives positive CHMP opinion for pancreatic cancer treatment

Industry news / 25 July 2016 / Niamh Louise Marriott, Digital Content Producer

The positive opinion is based on a pivotal Phase 3 study showing that Onivyde combined with chemotherapy significantly increased overall survival in patients with metastatic pancreatic cancer…

Phase III enzalutamide trial initiated in mHSPC

Industry news / 29 March 2016 / Victoria White

The ARCHES trial will evaluate the efficacy and safety of enzalutamide with androgen deprivation therapy (ADT) versus placebo with ADT in mHSPC patients…

NICE recommends abiraterone for some prostate cancer patients

Industry news / 21 March 2016 / Victoria White

Professor Paul Workman of The Institute of Cancer Research, which discovered abiraterone, said the recommendation was “a big victory for men”…

First patient dosed in Halozyme’s PEGPH20 pancreatic cancer trial

Industry news / 17 March 2016 / Victoria White

The trial will study PEGPH20 in combination with nab-paclitaxel and gemcitabine in patients with tumours that accumulate high levels of hyaluronan…

Abiraterone acetate plus prednisone shows survival benefit in early mCRPC

Industry news / 14 March 2016 / Victoria White

In a study, abiraterone acetate plus prednisone provided an 11.8 months overall survival benefit compared to an active control of placebo plus prednisone…

Celgene’s Imnovid and Abraxane recommended for use in Ireland

Industry news / 29 February 2016 / Victoria White

Celgene has announced that that of the Health Service Executive (HSE) of Ireland has recommended two cancer treatments: Imnovid and Abraxane…

Incyte discontinues JANUS 1 study of ruxolitinib plus capecitabine

Industry news / 11 February 2016 / Victoria White

Incyte has explained that its decision to stop the study was made after a planned interim analysis of JANUS 1 demonstrated that ruxolitinib plus capecitabine did not show a sufficient level of efficacy to warrant continuation.

RedHill Biopharma and IZI enter RP101 collaboration

Industry news / 8 February 2016 / Victoria White

The research collaboration will test RP101 in preclinical oncology models in combination with standard-of-care chemotherapies to support existing Phase I and Phase II clinical data…

FDA grants Breakthrough Therapy designation to Lynparza in mCRPC

Industry news / 28 January 2016 / Victoria White

This Lynparza BTD is for the treatment of BRCA1/2 or ATM gene mutated metastatic Castration Resistant Prostate Cancer…

STRIVE results for enzalutamide in CRPC published

Industry news / 27 January 2016 / Victoria White

The study achieved its primary endpoint demonstrating a statistically significant increase in PFS for enzalutamide compared with bicalutamide…

  • Page 1 of 2
  • 1
  • 2
  • >


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...